According to a JPMorgan report, China's innovative drug sector has evolved from being an 'optional choice' to becoming a category that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. In certain areas such as oncology, autoimmune diseases, and metabolic conditions, some Chinese pharmaceutical companies have advanced to the forefront of global competition for the same therapeutic targets. This leadership is not primarily reflected in innovation of mechanisms but rather in clinical execution efficiency, patient enrollment speed, and the pace of advancing indications.
At the latest JPMorgan Global Healthcare Conference, discussions surrounding mergers and acquisitions (M&A) and external licensing (business development, BD) among multinational pharmaceutical companies have notably intensified, with innovative drug assets originating from China repeatedly becoming a central topic of discussion.
According to TradingView, JPMorgan’s latest report analyzes the evolving role of China's innovative drug sector in global asset allocation based on industrial signals reflected at the conference, starting from the perspective of R&D and capital constraints faced by multinational pharmaceutical enterprises.
JPMorgan’s conclusion is not a blanket statement of 'comprehensive rise of China's pharmaceutical industry,' but rather a more specific and limited judgment: in several technology platforms and therapeutic areas, China’s innovative drugs have evolved from being an 'optional asset' to becoming a category that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. However, this shift heavily depends on clinical data, development timelines, and globalization capabilities and does not apply universally.
As M&A becomes a survival tool, the 'availability' of external assets has begun to be repriced.
The report highlights that at this year’s conference, multinational pharmaceutical companies repeatedly emphasized the importance of supplementing pipelines through M&A and licensing deals. The underlying reasons are straightforward: the concentration of core patent expirations, declining internal R&D return rates, and intensifying competition in key therapeutic fields have made reliance solely on in-house R&D uneconomical in terms of both time and risk.
Under such constraints, the criteria for selecting external assets have shifted. Multinational pharmaceutical companies are now focusing not only on technological concepts but also on whether these assets can advance into late-stage clinical or registration phases within a controllable timeframe.
It is under this selection logic that certain innovative drug assets originating from China have moved to the forefront of discussions—not because of 'national advantages' but because they have reached a level of maturity capable of integrating with global development systems in specific areas.
The prerequisite for attention on China's innovative drugs lies in clinical progress rather than cost advantages.
It should be clarified that the growing attention on China’s innovative drugs does not mean their overall cost advantage is being 'premium-priced.' In fact, in decision-making by multinational pharmaceutical firms, R&D costs are only secondary variables, with time and certainty being far more critical.
The report notes that in some oncology, autoimmune, and metabolic indications, projects from certain Chinese pharmaceutical companies have already taken leading positions in global target-based competition. This leadership is not reflected in innovation mechanisms themselves but rather in clinical execution efficiency, patient enrollment speed, and the pace of indication advancement.
When an asset has the opportunity to enter a critical clinical stage earlier, its commercial potential will naturally be assessed in advance. This is the main reason why Chinese assets are systematically included in evaluations, rather than simply being 'undervalued'.
Out-licensing is becoming a risk-sharing tool rather than a one-way value transfer.
Structurally, out-licensing at this stage serves more as a risk management tool rather than a passive monetization strategy. For Chinese innovative drug companies, the core role of out-licensing lies in:
On the one hand, leveraging multinational pharmaceutical companies' clinical, regulatory, and commercialization systems reduces uncertainty for a single company in global development; on the other hand, it shifts the valuation logic of assets from a single regional market to broader global sales assumptions.
However, this mechanism does not automatically apply. Only when the asset itself has a clear clinical positioning and scalability can out-licensing truly amplify its long-term value; otherwise, licensing deals are more likely to be one-time financial arrangements.
The current changes resemble an 'upgrade in the screening mechanism' rather than a wholesale industry revaluation.
Based on information released at the conference, a more accurate description is not that 'Chinese pharmaceuticals are entering the global core,' but rather that multinational pharmaceutical companies are tightening and advancing their screening mechanisms for external assets. In this process, some Chinese innovative drug projects have entered the range of comparison and benchmarking due to their progress and data quality.
This means that the internal differentiation within China's pharmaceutical sector will further intensify. Projects that can enter the global evaluation system may receive higher capital attention, while projects unable to provide clear clinical value may see a decline in marginal attractiveness.
From an investment perspective, what is truly worth tracking is whether specific projects possess the following characteristics:
Whether clinical data demonstrates differentiation or clear positioning, whether it can smoothly enter multi-regional clinical and registration pathways, and whether it has realistic feasibility for integration by multinational pharmaceutical companies.
Only under these conditions can China's innovative drug projects transition from being 'comparative subjects' to becoming 'transactional assets'.
Risks remain primarily concentrated in clinical outcomes and timing mismatches.
It is important to emphasize that the current trend does not diminish the inherent risks of the pharmaceutical industry. Clinical failures, shifts in competitive dynamics, and regulatory uncertainties may still significantly impact the valuation of individual assets. Moreover, if market expectations regarding mergers and acquisitions or out-licensing are overly front-loaded, this could also lead to periodic valuation volatility.
Therefore, assessing the global potential of China's innovative drugs should always be based on verifiable data and pathways, rather than on narrative-driven trends alone.
Overall, what the JPMorgan Global Healthcare Conference reflects is not emotional optimism toward China's pharmaceutical sector but rather a more pragmatic and efficiency-oriented reassessment by the global pharmaceutical industry of external innovation sources under resource constraints. In this process, China’s innovative drugs have entered the 'must-evaluate' category in certain fields, but this does not imply a broad-based revaluation. The key determinant going forward will not be whether it originates from China, but whether it possesses the ability to be continuously validated and absorbed by the global system.
Editor/Jayden